AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
August 18, 2021 07:05 ET | AzurRx BioPharma, Inc.
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
August 17, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
August 16, 2021 08:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares
July 27, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
July 22, 2021 16:51 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
gmi logo.jpg
Prenatal and New-born Genetic Testing Market revenue to cross USD 9.5 Bn by 2027: Global Market Insights Inc.
July 07, 2021 05:00 ET | Global Market Insights, Inc
Selbyville, Delaware, July 07, 2021 (GLOBE NEWSWIRE) -- According to latest report “Prenatal and New-born Genetic Testing Market by Technology (Screening, Diagnostic), Disease (Downs Syndrome,...
Claire’s Place Foundation Partners with Woojer to Launch SICK BEATS
June 21, 2021 12:39 ET | Claire's Place Foundation
Los Angeles, CA, June 21, 2021 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
June 08, 2021 07:00 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
June 07, 2021 07:00 ET | AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx...